Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer

Yamaki, Sayaka; Fujii, Takaaki; Yajima, Reina; Hirakata, Tomoko; Yamaguchi, Satoru; Fujisawa, Tomomi; Tsutsumi, Soichi; Asao, Takayuki; Yanagita, Yasuhiro; Iijima, Misa; Kuwano, Hiroyuki

doi:10.1007/s00595-012-0378-3

Cited by 27 publications

(17 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravasation of primary tumor into either vasculature or lymphatics primarily occurs through the angiogenic or lymphangiogenic vessels rather than via the dormant vessels[31]. As tumor lymphangiogenesis and angiogenesis take place with different pro-angiogenic factors secreted by tumor cells[32,33], intravasation into either microvascular or lymphatic systems is thought to depend on different processes, and some studies have been demonstrated it[34]. Regarding the results from the current study that Romo1 correlates with only lymphatic invasion but not vascular invasion, we suppose that Romo1 could induce specific signals that promote lymphangiogenesis in CRC.…”

Section: Discussionmentioning

confidence: 99%

Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

Kim

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

BackgroundReactive oxygen species modulator-1 (Romo1) is a novel protein that has been reported to be crucial for cancer cell proliferation and invasion. However, its clinical implications in colorectal cancer patients are not well-known. For the first time, we investigated the association between Romo1 and the clinical outcomes of colorectal cancer patients.StudyWe examined Romo1 expression in resected tumor tissues immunohistochemically and assessed it with histological scores. We conducted survival analyses for patients who had curative resection (n = 190) in accordance with clinical parameters including level of Romo1 expression, and we examined the association between Romo1 expression and cell invasion using Matrigel invasion assay in colorectal cancer cells.ResultsWe observed significantly longer mean disease-free survival in the low Romo1 group compared with the high Romo1 group (161 vs 127.6 months, p = 0.035), and the median overall survival of the low Romo1 group was significantly longer than that of the high Romo1 group (196.9 vs 171.3 months, p = 0.036). Cell invasiveness decreased in the Romo1 knockdown colorectal cancer cells in contrast to the controlled cells. Romo1 overexpression in tumor tissue was associated with a high lymph node ratio between the metastatic and examined lymph nodes (p = 0.025).ConclusionsRomo1 overexpression in tumor tissue was significantly associated with survival in curatively resected colorectal cancer patients, suggesting Romo1 expression as a potential adverse prognostic marker. Increased Romo1 expression was found to be associated with high lymph node ratio. Cancer invasiveness appeared to be a key reason for the poor survival related to highly expressed Romo1.

show abstract

Section: Discussionmentioning

confidence: 99%

Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

Kim

et al. 2017

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…The prognostic value of galectin-3 expression in cancer patients is still a subject of discussion (76, 98). Nonetheless, galectin-3 has emerged as a useful parameter in diagnosis and/or prognosis of some malignancies (99–101).…”

Section: Concluding Remarks and Future Perspectivesmentioning

confidence: 99%

Extracellular Galectin-3 in Tumor Progression and Metastasis

et al. 2014

View full text Add to dashboard Cite

Galectin-3, the only chimera galectin found in vertebrates, is one of the best-studied galectins. It is expressed in several cell types and is involved in a broad range of physiological and pathological processes, such as cell adhesion, cell activation and chemoattraction, cell cycle, apoptosis, and cell growth and differentiation. However, this molecule raises special interest due to its role in regulating cancer cell activities. Galectin-3 has high affinity for β-1,6-N-acetylglucosamine branched glycans, which are formed by the action of the β1,6-N-acetylglucosaminyltransferase V (Mgat5). Mgat5-related changes in protein/lipid glycosylation on cell surface lead to alterations in the clustering of membrane proteins through lattice formation, resulting in functional advantages for tumor cells. Galectin-3 presence enhances migration and/or invasion of many tumors. Galectin-3-dependent clustering of integrins promotes ligand-induced integrin activation, leading to cell motility. Galectin-3 binding to mucin-1 increases transendothelial invasion, decreasing metastasis-free survival in an experimental metastasis model. Galectin-3 also affects endothelial cell behavior by regulating capillary tube formation. This lectin is found in the tumor stroma, suggesting a role for microenvironmental galectin-3 in tumor progression. Galectin-3 also seems to be involved in the recruitment of tumor-associated macrophages, possibly contributing to angiogenesis and tumor growth. This lectin can be a relevant factor in turning bone marrow in a sanctuary for leukemia cells, favoring resistance to therapy. Finally, galectin-3 seems to play a relevant role in orchestrating distinct cell events in tumor microenvironment and for this reason, it can be considered a target in tumor therapies. In conclusion, this review aims to describe the processes of tumor progression and metastasis involving extracellular galectin-3 and its expression and regulation.

show abstract

“…However, in pancreatic carcinoma 24) , laryngeal squamous-cell carcinoma 25) , gastric carcinoma 26) , clear cell renal carcinoma 27) , and breast carcinoma 28) , said overexpression has been reported to be associated with better prognosis. As for the relationship between galectin-3 and IPMN, there is one report describing that the gene expression of galectin-3 was about 4.88-fold upregulated in IPMN 29) .…”

Section: Intranuclear Accumulation Of Galectin-3 Is Associated With Amentioning

confidence: 99%

Intranuclear accumulation of galectin-3 is associated with a poor prognosis in patients with invasive intraductal papillary mucinous neoplasm

Shimura

Kofunato

Okada

et al. 2016

Ann. Cancer Res. Therap.

Self Cite

View full text Add to dashboard Cite

Results:The intranuclear accumulation of galectin-3 (gal-3-INA) was more frequently encountered in patients with invasive IPMN than with non-invasive IPMN (P = 0.038). Incidences of background fibrosis and dilatation of the main pancreatic duct were higher in the high-galectin-3 expression group than in the low-galectin-3 expression group (P = 0.0041 and 0.006, respectively). Incidence of background fibrosis was also higher in patients with gal-3-INA than without gal-3-INA (P = 0.011). The presence of gal-3-INA was higher in the high-galectin-3 expression group than in the low-galectin-3 expression group (P = 0.014). The high-galectin-3-expression group and the patients with gal-3-INA had a significantly poorer prognosis than the low-galectin-3-expression group and those without gal-3-INA (P = 0.020 and P = 0.014, respectively). Multivariate analysis using a Cox regression model revealed that gal-3-INA was an independent prognostic factor (hazard ratio: 5.162, 95% confidential interval: 1.033-25.807, P = 0.046). Conclusions:The presence of gal-3-INA is an independent prognostic factor for patients with invasive IPMN.

show abstract

Clinicopathological significance of decreased galectin-3 expression and the long-term prognosis in patients with breast cancer

Cited by 27 publications

References 11 publications

Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

Reactive oxygen species modulator-1 (Romo1) predicts unfavorable prognosis in colorectal cancer patients

Extracellular Galectin-3 in Tumor Progression and Metastasis

Intranuclear accumulation of galectin-3 is associated with a poor prognosis in patients with invasive intraductal papillary mucinous neoplasm

Contact Info

Product

Resources

About